Olema Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stock holders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income/(Loss) · Deficit · Equity
Balances at June 30, 2026	87,452,166	$	8	$	1,145,349	$	(947)	$	(713,846)	$	430,564
Stock-based compensation expense, including employee stock purchase plan expense	—		—		12,082		—		—		12,082
Exercise of stock options	85,658		—		434		—		—		434
Net unrealized loss on marketable securities	—		—		—		(644)		—		(644)
Net loss	—		—		—		—		(73,599)		(73,599)
Balances at September 30, 2026	87,537,824	$	8	$	1,157,865	$	(1,591)	$	(787,445)	$	368,837
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income/(Loss) · Deficit · Equity
Balances at December 31, 2025	81,376,449	$	8	$	1,075,487	$	621	$	(597,557)	$	478,559
Exchange of pre-funded warrants for common stock shares	3,500,000		—		—		—		—		—
Issuance of shares under at-the-market offering, net of issuance costs of $40	1,712,739		—		41,918		—		—		41,918
Stock-based compensation expense, including employee stock purchase plan expense	—		—		35,133		—		—		35,133
Exercise of stock options	885,858		—		4,675		—		—		4,675
Issuance of shares under employee stock purchase plan	62,778		—		652		—		—		652
Net unrealized loss on marketable securities	—		—		—		(2,212)		—		(2,212)
Net loss	—		—		—		—		(189,888)		(189,888)
Balances at September 30, 2026	87,537,824	$	8	$	1,157,865	$	(1,591)	$	(787,445)	$	368,837

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at June 30, 2025		68,627,886	$		7		$		854,194			$	314			$	(509,279)			$	345,236
Stock-based compensation expense, including employee stock purchase plan expense	—		—				4,250				—			—				4,250
Exercise of stock options		24,844		—				7				—			—				7
Net unrealized loss on marketable securities	—		—			—					212			—				212
Net loss	—		—			—				—				(42,217)				(42,217)
Balances at September 30, 2025		68,652,730	$		7		$		858,451			$	526			$	(551,496)			$	307,488
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at December 31, 2024		74,312,608		$7		$		843,920				$143		$		(435,106)		$		408,964
Stock-based compensation expense, including employee stock purchase plan expense	—		—				13,320				—			—				13,320
Issuance of shares under employee stock purchase plan		206,609		—			748				—			—				748
Exercise of stock options		203,513		—			477				—			—				477
Issuance cost associated with private equity placement	—		—				(14)				—			—				(14)
Exchange of common stock shares for pre-funded warrants		(6,070,000)		—			—				—			—			—
Net unrealized gain on marketable securities	—		—			—				383			—				383
Net loss	—		—			—				—				(116,390)				(116,390)
Balances at September 30, 2025		68,652,730		$7		$		858,451				$526		$		(551,496)		$		307,488

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.